TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2022

Updated: May 5

REVENUES OF TOP BIOPHARMACEUTICAL COMPANIES 2022

1 CHF = 1.04 USD

Merck revenues include only pharmaceuticals (excluding animal health)

 

PFIZER

Q1 REVENUES

Pfizer reported revenues of $25.7 billion in the first quarter of 2022, reflecting operational growth of 82%. The revenues from the vaccines segment were $14.94 billion, the hospital segment was $3.19 billion, the oncology segment was $2.97 billion, and immunology was $820 million.

The revenue drivers of the company were Comirnaty ($13.23 billion), Prevnar family ($1.57 billion), Paxlovid ($1.47 billion), Eliquis ($ 1.79 billion), and Ibrance ($1.24 billion).


 

JOHNSON AND JOHNSON

Q1 RESULTS

Johnson and Johnson reported revenues of $23.4 billion in the first quarter of 2022, with sales growth of 5.0%. Pharmaceutical segment revenues were $12.87 billion, consumer health revenues were $3.59 billion, and Medtech revenues were $6.97 billion.

Stelara's revenues were $2.29 billion, and Darzalex's revenues were $1.86 billion.


 

ROCHE

Q1 RESULTS

Roche sales increased by 11% at a constant exchange rate; pharmaceutical sales increased by 6%, and the diagnostics division grew by 24%. In the US, the pharmaceutical division sales increased by 2%, decreased by 1% in Europe, and increased by 69% in Japan primarily because of the high demand of COVID19 drug Ronapreve.


The main revenue drivers in the pharmaceutical segment were Ocrevus ($1.5 billion), Perjeta ($1.03 billion), Hemlibra ($0.89 billion), Tecentriq ($0.86 billion), and Actemra ($0.83 billion).


However, the company's full-year outlook mentioned sales growth in the low single digits, primarily because of a decrease in the demand for COVID19 drugs and diagnostics (sales decrease from CHF 2 billion 5 billion), plus losses due to biosimilars (CHF 2.5 billion).

 

MERCK

Q1 RESULTS

Merck reported revenues of $15.9 billion, and the pharmaceutical segment contributed $14.1 billion. Animal health contributed revenues of $1.5 billion.

The sales were primarily driven by Keytruda ($4.8 billion) and Lagevrio ($3.25 billion).

 

ABBVIE

Q1 RESULTS

AbbVie's Q1 revenues in 2022 were $13.5 billion, an increase of 4.1%. The revenues from the immunology portfolio were $6.14 billion, neuroscience was $1.5 billion, and hematologic oncology was $1.65 billion.

Humira revenues were $3.99 billion, Imbruvica was $1.17 billion, and Skyrizi was $0.94 billion.

 

NOVARTIS

Q1 RESULTS

Novartis sales increased by 5% at a constant exchange rate; innovative medicines sales grew by 4%.

The main revenue drivers are Cosentyx ($1.16 billion), Entresto ($1.09 billion), Gilenya ($0.6 billion), and Lucentis ($0.52 billion).

 

GSK

Q1 RESULTS

GSK reported revenues of $12.3 billion in the first quarter of 2022 (£9.8 billion), a revenue increase of 32% at a constant exchange rate. The biopharmaceutical segment contributed $8.9 billion; consumer health contributed $3.3 billion.

The best-selling drugs were Xevudy ($1.63 billion) and dolutegravir products ($1.38 billion).

 

ABBOTT

Q1 RESULTS

Abbott reported revenues of $11.90 billion in Q1 of 2022. The sales from the nutrition segment were $1.89 billion, diagnostics were $5.29 billion, medical devices were $3.57 billion, and pharmaceuticals were $1.15 billion.

 

BMS

Q1 RESULTS

BMS reported the Q1 revenues of $11.6 billion in 2022. The company's revenues were driven by Eliquis ($3.2 billion), Revlimid ($2.8 billion), Opdivo ($1.9 billion), Pomalyst / Imnovid (0.83 billion), and Orencia (0.79 billion).

1 comment

Recent Posts

See All